ストックスクリーナーアプリを入手
32.96
0.46%
0.15
アフターアワーズ：
32.96
前日終値:
$32.81
開ける：
$32.81
24時間の取引高:
317.86K
Relative Volume:
0.52
時価総額：
$1.57B
収益：
-
当期純損益:
$-86.97M
株価収益率:
-13.63
EPS:
-2.4189
ネットキャッシュフロー:
$-81.88M
1週間 パフォーマンス:
+4.11%
1か月 パフォーマンス:
+17.71%
6か月 パフォーマンス:
+136.27%
1年 パフォーマンス:
+346.61%
1日の値動き範囲:
$31.82
$33.50
1週間の範囲:
$30.76
$33.80
52週間の値動き範囲:
$7.09
$44.89
Mbx Biosciences Inc Stock (MBX) Company Profile
Compare MBX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
32.96 | 1.56B | 0 | -86.97M | -81.88M | -2.4189 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 開始されました | Barclays | Overweight |
| 2025-12-04 | 開始されました | Goldman | Sell |
| 2025-11-04 | 開始されました | TD Cowen | Buy |
| 2025-10-15 | 開始されました | Truist | Buy |
| 2025-08-15 | 再開されました | Jefferies | Buy |
| 2025-08-05 | 開始されました | Mizuho | Outperform |
| 2025-07-16 | 開始されました | Oppenheimer | Outperform |
| 2025-04-10 | 開始されました | Citizens JMP | Mkt Outperform |
| 2024-10-08 | 開始されました | Guggenheim | Buy |
| 2024-10-08 | 開始されました | JP Morgan | Overweight |
| 2024-10-08 | 開始されました | Jefferies | Buy |
| 2024-10-08 | 開始されました | Stifel | Buy |
すべてを表示
Mbx Biosciences Inc (MBX) 最新ニュース
Stifel reiterates Buy on MBX Biosciences stock, keeps $50 target - Investing.com
Is MBX Biosciences Inc stock influenced by commodity pricesWeekly Earnings Recap & Daily Growth Stock Tips - baoquankhu1.vn
Goldman Sachs initiates coverage of MBX Biosciences (MBX) with sell recommendation - MSN
MBX Biosciences (NASDAQ:MBX) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
MBX Biosciences, Inc. focuses on science-led innovation to transform endocrine and metabolic disease treatment - Traders Union
MBX Biosciences (NASDAQ:MBX) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Institution Moves: Is MBX Biosciences Inc part of any ETF2026 Sector Review & Technical Entry and Exit Tips - baoquankhu1.vn
Does MBX (MBX) Options-Driven Breakout Reveal Deeper Shifts In Its Investment Narrative? - Yahoo Finance
MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sahm
MBX Biosciences (MBX) Is Up 16.6% After Analyst Initiation And Leadership Award News Has The Bull Case Changed? - Sahm
MBX Biosciences Approves Equity-Based Inducement Grant for New Employee Under Nasdaq Rule - geneonline.com
MBX Biosciences Reports Inducement Grant - National Today
Lifesci Capital Weighs in on MBX Biosciences Q1 Earnings - MarketBeat
MBX Biosciences (NASDAQ:MBX) Upgraded at Lifesci Capital - MarketBeat
MBX Biosciences (NASDAQ:MBX) Shares Up 8.5%What's Next? - MarketBeat
MBX Biosciences, Inc. (NASDAQ:MBX) Sees Large Increase in Short Interest - MarketBeat
MBX PE Ratio & Valuation, Is MBX Overvalued - Intellectia AI
221,672 Shares in MBX Biosciences, Inc. $MBX Acquired by Goelzer Investment Management Inc. - MarketBeat
MBX CEO Buys 18,500 Shares as Stock Jumps 270% This Past Year. Here's What You Should Know - Yahoo Finance
Wall Street Analysts See a 280.14% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High? - MSN
MBX Biosciences, Inc. (NASDAQ:MBX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
MBX (NASDAQ: MBX) affiliate files sale notice for 1,061 vested shares - Stock Titan
MBX Biosciences (MBX) Is Down 6.5% After Wider Losses And New Shelf Filings Has The Bull Case Changed? - simplywall.st
Hudson Bay Capital Management LP Purchases New Stake in MBX Biosciences, Inc. $MBX - MarketBeat
Aug Intraday: Can MBX Biosciences Inc keep up with sector leaders2026 Risk Factors & AI Powered Trade Plan Recommendations - baoquankhu1.vn
MBX Biosciences Advances Avail Phase 2 Trial in Hypoparathyroidism: What Investors Should Watch - TipRanks
Top MBX Biosciences (MBX) Competitors 2026 - MarketBeat
New weekly therapy moves toward Phase 3 for hypoparathyroidism - Hypoparathyroidism News
MBX Biosciences (MBX) CFO John Smither files initial Form 3 - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
MBX Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MBX Biosciences Chief Makes Bold Insider Move With Major Stock Buy - TipRanks
Company (NASDAQ: MBX) Form 144 — 10,000-share sale notice via Fidelity - Stock Titan
MBX Biosciences (NASDAQ:MBX) Shares Gap Up After Insider Buying Activity - MarketBeat
A Look At MBX Biosciences (MBX) Valuation After Recent Share Price Pullback - simplywall.st
Hawryluk P. Kent buys MBX Biosciences shares worth $525,662 By Investing.com - Investing.com India
Hawryluk P. Kent buys MBX Biosciences shares worth $525,662 - Investing.com
MBX Biosciences (NASDAQ:MBX) CEO Buys $525,585.00 in Stock - MarketBeat
MBX Biosciences (MBX) CEO adds 18,500 shares via trust purchase - Stock Titan
MBX Phase 3 Plans And New CBO Sharpen Rare Disease Focus - Yahoo Finance
Baker BROS. Advisors LP Takes $4.86 Million Position in MBX Biosciences, Inc. $MBX - MarketBeat
MBX Biosciences completes FDA meeting for Phase 3 trial design - Investing.com Nigeria
Ghisallo Capital Management LLC Takes $669,000 Position in MBX Biosciences, Inc. $MBX - MarketBeat
Wall Street Analysts See a 142% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High? - MSN
Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX) and REPRO-MED Systems (KRMD) - The Globe and Mail
MBX Biosciences Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView
Citizens reiterates Market Outperform on MBX Biosciences stock - Investing.com Nigeria
Mbx Biosciences Inc (MBX) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):